Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.364 USD | +4.96% | -1.17% | -12.50% |
Sales 2024 * | 7.3M 5.39M | Sales 2025 * | 9.12M 6.74M | Capitalization | 2.98M 2.2M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.41 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.33 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.64% |
Latest transcript on InMed Pharmaceuticals Inc.
1 day | +4.96% | ||
1 week | -1.17% | ||
Current month | -12.29% | ||
1 month | -13.33% | ||
3 months | -6.19% | ||
6 months | -47.25% | ||
Current year | -12.50% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-15 |
Chief Operating Officer | - | 18-11-04 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 22-02-10 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16-06-15 |
Andrew Hull
CHM | Chairman | 61 | 16-09-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.364 | +4.96% | 59,806 |
24-03-27 | 0.3468 | +0.49% | 62,624 |
24-03-26 | 0.3451 | -4.14% | 76,604 |
24-03-25 | 0.36 | -5.21% | 60,538 |
24-03-22 | 0.3798 | +3.12% | 64,220 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.50% | 2.1M | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |